Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Researchers identify role of Merlin in regulating integrity of axons

Researchers identify role of Merlin in regulating integrity of axons

Drugs that inhibit buildup of acylcarnitines may block axonal degeneration

Drugs that inhibit buildup of acylcarnitines may block axonal degeneration

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept fourth quarter revenue decreases to $0.1 million

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Diabetic peripheral neuropathy risk highlighted in children

Diabetic peripheral neuropathy risk highlighted in children

Boston College biologist to explore connection between peripheral neuropathy and HIV

Boston College biologist to explore connection between peripheral neuropathy and HIV

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Gait abnormalities found in diabetic neuropathy

Gait abnormalities found in diabetic neuropathy

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Companionship can reduce nerve-related pain

Companionship can reduce nerve-related pain

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.